GemVax Introduces GV1001 at Dementia Forum X, One of the World's Top 3 International Dementia Forums

[Asia Economy Reporter Hyunseok Yoo] GemVax announced on the 26th that its Alzheimer's disease treatment ‘GV1001’ will be introduced at Dementia Forum X KOREA, held at COEX from the 25th to the 27th of next month.

Dementia Forum X (DFX) is a global dementia forum that started in 2015 under the Swedish royal family. This forum will be attended by the heads of the world's top three dementia organizations?the Alzheimer's Disease International (ADI) and the Alzheimer's Association (AA)?along with DFX organizer SCI (Swedish Care International), sharing the latest global trends in the dementia industry.

In particular, on the second day of the event, Philip Scheltens, an overseas advisory board member of GemVax and a world-renowned expert in the field of Alzheimer's disease and director of the Alzheimer Center at Vrije Universiteit Amsterdam, will explain GV1001 during his presentation on Alzheimer's disease treatment research and achievements.

GV1001 is a peptide drug composed of 16 amino acids derived from telomerase. Based on the results of a phase 2 clinical trial of GV1001 conducted in South Korea, GemVax revealed significant improvement in the primary endpoint, the Severe Impairment Battery (SIB) score (7.11 points), as well as outstanding statistical significance in secondary endpoints such as the Neuropsychiatric Inventory (NPI) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL).

Currently, GemVax is preparing for a domestic phase 3 clinical trial based on these results. Recently, the U.S. Food and Drug Administration (FDA) proposed an indication expansion for the phase 2 trial, and GemVax plans to apply for approval of clinical trials expanding indications to include mild Alzheimer's disease and mild cognitive impairment (MCI), in addition to the already approved trials for patients with moderate or greater Alzheimer's disease in the U.S.

Overseas advisory board members stated, “The phase 2 clinical trial analysis showed significant improvement in key indicators such as the Severe Impairment Battery (SIB) and activities of daily living assessments among patients with moderate or greater Alzheimer's disease. Considering these results, it is possible to develop GV1001 as a treatment covering the entire spectrum of dementia stages by expanding indications to mild Alzheimer's disease and mild cognitive impairment (MCI).”

A GemVax official said, “We will strive to present a new paradigm for dementia treatment based on telomerase-derived new drug candidates,” adding, “We will also proceed smoothly with the domestic phase 3 clinical trial and global phase 2 clinical trial of the Alzheimer's disease treatment GV1001 to expedite its commercialization.”